SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

SYRE

Spyre Therapeutics, Inc.
BEARISH
Impact 7/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Traders should anticipate near-term downward pressure on the stock due to dilution; monitor for insider selling patterns and pricing relative to current market levels, which could signal management's confidence.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$64.01
T+0 close · Apr 13, 2026 · via day close
Latest settled
+54.27%
T+60 · $98.75
Vs SPY
+45.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $64.01entry
  2. T+1 · 7mo ago +7.78%α +7.01% · $68.99
  3. T+5 · 7mo ago +11.34%α +9.95% · $71.27
  4. T+20 · 6mo ago +19.40%α +13.11% · $76.43
  5. T+60 · 4mo ago +54.27%α +45.75% · $98.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics announced a $300 million public offering of common stock, with underwriters expected to receive a 30-day option to purchase up to an additional $45 million in shares. The proceeds will be used for general corporate purposes, including funding clinical development programs in IBD and immune-mediated diseases.

Key Financial Metrics

Deal Value
$345.0M

Key Facts

  • Spyre Therapeutics is conducting a $300 million public offering of common stock.
  • Underwriters are expected to receive a 30-day option to purchase up to an additional $45 million in shares.
  • All shares are being sold by the company, indicating primary issuance and dilution to existing shareholders.
  • Proceeds will support clinical development and general corporate purposes.

Financial Impact

$300 million raised, potentially $345 million with overallotment; significant dilution expected

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from new share issuance
  • Potential downward pressure on stock price if offering is priced at a discount

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272916

Track record

36 reports on SYRE

Performance horizon

8 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 20 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026